As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Newly Diagnosed Classical Hodgkin Lymphoma Treatment Study

Clinical Trial Title: 
A randomized phase 3 study of brentuximab vedotin (SGN-35, IND #117117) for newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults.
Clinical Trial Protocol ID: 
15070801-CAO1
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

Response directed therapy in high risk pediatric Hodgkin lymphoma with brentuximab added to standard therapy.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are between 2 and 22 years of age at the time of enrollment.
  • Have newly  diagnosed, pathologically confirmed cHL meeting one of the following Ann Arbor stages:
    • Stage IIB with bulk
    • Stage IIIB
    • Stage IVA
    • Stage IVB

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Pediatric Cancers and Blood Disorders
Contact Phone: 
(312) 355-0741
Contact Name: 
Nitin Sane